CRDF   $2.45  -2.00% Market Closed After Close 2.46 0.41%

Cardiff Oncology Inc
Last Events:

2023-08-09 Trend pattern changed from расходящийся клин с наклоном вниз to расширяющаяся формация.

2023-08-09 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-09 Signal in MACD changed from bullish to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: signal line crossed the middle level.

2023-08-09 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: exit from the overbought zone.

2023-08-09 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-09 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-06 Signal in RSI changed from bearish reversal to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.

2023-08-05 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it falls. These factors indicate that the downside trend is confirmed. Last signal: main and signal line crossing.


Current temperature: 3.85
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 3
Target Price Mean 9.33
Mean unverified/preliminary 9.33 / 9.33
Target Price Low / High 7.00 / 13.00
Median / STD DEV 8.00 / 3.21
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Sell Sell
rsi Sell Sell Sell
macd None None None
stoch None None None
ma20 ActivelyBuy Sell None
ma50 ActivelyBuy None None
ma100 None None None
Candlestick PatternNov. 19, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US14147L1089
ceo Dr. Mark Erlander Ph.D.
Website https://www.cardiffoncology.com
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.